icon-folder.gif   Conference Reports for NATAP  
 
  XVI International AIDS Conference
Toronto Canada
August 13 - 18, 2006
Back grey_arrow_rt.gif
 
 
 
Kaletra Monotherapy Induction-Maintenance in Naives Compared to Efavirenz, 96 Weeks
 
 
  "A two-year randomised controlled clinical trial in antiretroviral-naïve subjects using lopinavir/ritonavir monotherapy after initial induction treatment compared to an efavirenz 3-drug regimen. 96 week results, Study M03-613"
 
Late Breaker Thursday 2:15pm oral session
Oral Presentation #THLB0201
 
Reported by Jules Levin
XVI Intl AIDS Conference, Toronto, Aug 17, 2006
 
Authors: DW Cameron1, BA da Silva2, JR Arribas3, R Myers4, NC Bellos5, N Gilmore6, KR Niemi2, KJ Wikstrom2, MS King2, GJ Hanna2, SC Brun2
 
1University of Ottawa at The Ottawa Hospital, Ottawa, Ontario, Canada
2Abbott Laboratories, Abbott Park, IL, USA
3Hospital La Paz, Madrid, Spain
4Body Positive, Inc., Phoenix, AZ, USA
5Southwest Infectious Disease Associates, Dallas, TX, USA
6Montréal Chest Institute, Montréal, Québec, Canada
 
Study design and methods
Treatment-naïve patients with no evidence of resistance, any CD4 & HIV-RNA>1000, randomized to receive Kaletra soft-gel capsules 400/100 bid + AZT/3TC (n=104) or EFV 600 mg qd +AZT/3TC (n=51). The study is a 96-week trial.
 

lpv-1.gif

VL monitored monthly for 18 months, then every 2 months through month 24.
 
In the LPV/r group, subjects with VL < 50 / mL for 3 consecutive months from month 3 to 11 discontinued ZDV/3TC at the next visit (earliest month 6), and remained on LPV/r monotherapy. Subjects not meeting these criteria remained on LPV/r + ZDV/3TC.
 
Primary outcome: HIV-1 viral load < 50 c/mL at week 96 (24 months)
Primary analysis: intention-to-treat, prior failure (> 50 c/mL x 2) = failure
 
DEMOGRAPHICS
Mean CD4 count at baseline was 227-250. Mean VL was 5.0 log in LPV/r and 4.8 log in EFV. 42% in LPV/r had >100,000 and 31% had >100,000 in EFV. About 80% were men. 28% Black in LPV/r and 33% in EFV, 6% Hispanic in LPV/r and 16% Hispanic in EFV.65% Caucasian in LPV/r and 63% in EFV.
 

Dispo-2.gif

Discon-3.gif

secondary-4.gif

time-5.gif

point-6.gif

Detection-7.gif

AUTHOR SUMMARY & CONCLUSIONS
With successful LPV/r + ZDV / 3TC treatment, subsequent LPV/r monotherapy continuously maintained VL suppression in a large proportion of patients.
 
Patients receiving LPV/r monotherapy experienced more VL breakthrough of 50 - 500 c/mL versus EFV + ZDV / 3TC:
-- LPV/r monotherapy VL breakthrough was usually 50 - 500 c/mL
-- VL breakthrough generally re-suppressed to < 50 c/mL
-- Detection of drug resistance mutations did not differ in proportion for LPV/r versus EFV
 
LPV/r monotherapy may provide an alternative treatment option for selected patients.